Has teclistamab been officially launched in the domestic market?

Teritolumab (Teclistamab), trade name Tecvayli , is a BCMA × developed by Johnson & Johnson (Janssen) CD3Bispecific antibody is mainly used to treat adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is administered by subcutaneous injection and can guide T cells to myeloma cells, thereby activating T cells to kill tumor cells. Teritusumab was approved for marketing in the United States and Europe in 2022 and was introduced into the Chinese market in 2024, marking my country's further opening up in the field of high-end tumor immunotherapy.

So far, teritusumab has been approved for marketing by the National Food and Drug Administration (NMPA) in China. It is indicated as monotherapy for adult patients with relapsed or refractory multiple myeloma who have received at least three treatments in the past. According to data released by Johnson & Johnson, the overall response rate (ORR) of teritusumab in Chinese patients reached 76.9%.

However, although teritusumab has been approved for marketing in China, it has not yet been included in the national medical insurance directory. This means that patients have to bear all the costs themselves when using the drug, which puts great financial pressure on them. Because it is an innovative immunotherapy with significant efficacy and is suitable for people with refractory multiple myeloma who have extremely limited treatment options. It has strong clinical value and is therefore expected to become a key drug candidate in the next one to two rounds of medical insurance negotiations.

In foreign markets, a box of the original research version of teritusumab is 153mg/1.7ml and sells for about more than 50,000 yuan. Since the drug has not yet been included in domestic medical insurance, patients have to bear all the costs themselves when using the drug, which puts great financial pressure on them. Some patients may consider purchasing drugs overseas or participating in clinical trials to obtain drug support, but these approaches have limitations in terms of accessibility and safety.

In general, teritusumab has been officially launched in the Chinese market, but it has not yet been included in medical insurance. When considering using this drug, patients should fully understand its efficacy and side effects, and conduct treatment under the guidance of a professional doctor. At the same time, it is recommended to pay attention to the dynamic changes in medical insurance policies in order to obtain relevant information in a timely manner.

Reference materials:https://www.drugs.com/